Acute gout attacks · people with chronic gout
Febuxostat 80 mg/day showed no clear difference in incidence of gout flares compared with placebo (low certainty).
1 finding from 1 review
Serum uric acid <6.0 mg/dL at final visit · people with chronic gout
Febuxostat 80 mg/day may leads to higher serum uric acid <6.0 mg/dL at final visit compared with placebo (low certainty).
1 finding from 1 review
pain ‐ 100mm VAS mm. Scale from: 0 to 100. · patients with pain management in rheumatoid arthritis
1 finding from 1 review
Withdrawals due to adverse events · patients with pain management in rheumatoid arthritis
Nefopam 60 mg tds showed no clear difference in withdrawal Due to adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Total adverse events · patients with pain management in rheumatoid arthritis
Nefopam 60 mg tds may leads to higher total adverse events compared with placebo (low certainty).
1 finding from 1 review
Pain (% reduction from baseline) VAS 100mm · patients with Knee pain in patients with rheumatoid arthritis
2 findings from 1 review
Pain at present McGill short form questionnaire ‐ Verbal rating scale (0‐5) · patients with pain management in rheumatoid arthritis
1 finding from 1 review
Quality of sleep · patients with pain management in rheumatoid arthritis
1 finding from 1 review
Withdrawals due to adverse events · patients with pain management in rheumatoid arthritis
Oromucosal cannabis (Sativex) showed no clear difference in withdrawal due to adverse events compared with placebo (low certainty).
1 finding from 1 review
Total adverse events · patients with pain management in rheumatoid arthritis
Oromucosal cannabis (Sativex) may leads to higher total adverse events compared with placebo (low certainty).
1 finding from 1 review
Pain ‐ 24hrs (Single dose) · patients with pain management in rheumatoid arthritis
1 finding from 1 review
Pain ‐ 1‐2 weeks · patients with pain management in rheumatoid arthritis
1 finding from 1 review
Withdrawals due to adverse events · patients with pain management in rheumatoid arthritis
It is very uncertain whether muscle relaxant changes withdrawal due to Adverse Events compared with control (very low certainty).
1 finding from 1 review
Total Number of Adverse Events ‐ only studies >24hrs duration · patients with pain management in rheumatoid arthritis
It is very uncertain whether muscle relaxant changes total Number of Adverse Events ‐ only studies >24hrs duration compared with control (very low certainty).
1 finding from 1 review
Total Number of Adverse Events ‐ single dose studies · patients with pain management in rheumatoid arthritis
It is very uncertain whether muscle relaxant changes total Number of Adverse Events ‐ single dose studies compared with control (very low certainty).
1 finding from 1 review
CNS adverse events · patients with pain management in rheumatoid arthritis
It is very uncertain whether muscle relaxant changes CNS adverse events compared with control (very low certainty).
1 finding from 1 review
Pain (VAS) VAS from: 0 to 10 · patients with fibromyalgia
1 finding from 1 review
Tender points Tender point score and number of tender points · patients with fibromyalgia
1 finding from 1 review
Global assessment (by patient) VAS from: 0 to 10 · patients with fibromyalgia
1 finding from 1 review
Physical function · patients with fibromyalgia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found